DNA methylation and cancer

Journal of Clinical Oncology

Volumn 22, Issue 22, 2004, Pages 4632-4642

  Das, Partha M ^a   Singal, Rakesh ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); AZACITIDINE; COMPLEMENTARY DNA; FOLIC ACID; HISTONE DEACETYLASE INHIBITOR; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT;

BODY FLUID; CANCER; CANCER TISSUE; CARCINOGENESIS; DNA METHYLATION; ENZYME POLYMORPHISM; GENE SILENCING; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR; TUMOR SUPPRESSOR GENE; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETICS; NEOPLASM; PATHOPHYSIOLOGY; RISK FACTOR;

ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HUMANS; NEOPLASMS; PROGNOSIS; RISK FACTORS;

EID: 16544395591     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.07.151     Document Type: Review

References (131)

1. Singal R, Ginder GD: DNA methylation. Blood 93:4059-4070, 1999
2. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428, 2002
3. Baylin SB: Tying it all together: Epigenetics, genetics, cell cycle, and cancer. Science 277:1948-1949, 1997
4. Costello JF, Plass C: Methylation matters. J Med Genet 38:285-303, 2001
5. Laird PW: The power and the promise of DNA methylation markers. Nat Rev Cancer 3:253-266, 2003
6. Amir RE, Van den Veyver IB, Wan M, et al: Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 23:185-188, 1999
7. Ramsahoye BH, Biniszkiewicz D, Lyko F, et al: Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc Natl Acad Sci U S A 97:5237-5242, 2000
8. Antequera F, Bird A: CpG islands. Exs 64:169-185, 1993
9. Bird AP: CpG-rich islands and the function of DNA methylation. Nature 321:209-213, 1986
10. Antequera F, Bird A: Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci U S A 90:11995-11999, 1993
11. Cross SH, Bird AP: CpG islands and genes. Curr Opin Genet Dev 5:309-314, 1995
12. Robertson KD: DNA methylation and chromatin: Unraveling the tangled web. Oncogene 21:5361-5379, 2002
13. Szyf M: Targeting DNA methylation in cancer. Ageing Res Rev 2:299-328, 2003
14. Fremont M, Siegmann M, Gaulis S, et al: Demethylation of DNA by purified chick embryo 5-methylcytosine-DNA glycosylase requires both protein and RNA. Nucleic Acids Res 25:2375-2380, 1997
15. Bhattacharya SK, Ramchandani S, Cervoni N, et al: A mammalian protein with specific demethylase activity for mCpG DNA. Nature 397: 579-583, 1999
16. Ng HH, Zhang Y, Hendrich B, et al: MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat Genet 23:58-61, 1999
17. Wade PA, Gegonne A, Jones PL, et al: Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat Genet 23:62-66, 1999
18. Jones PA, Laird PW: Cancer epigenetics comes of age. Nat Genet 21:163-167, 1999
19. Rhee I, Bachman KE, Park BH, et al: DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416:552-556, 2002
20. Laird PW, Jackson-Grusby L, Fazeli A, et al: Suppression of intestinal neoplasia by DNA hypomethylation. Cell 81:197-205, 1995
21. Trinh BN, Long TI, Nickel AE, et al: DNA methyltransferase deficiency modifies cancer susceptibility in mice lacking DNA mismatch repair. Mol Cell Biol 22:2906-2917, 2002
22. Gaudet F, Hodgson JG, Eden A, et al: Induction of tumors in mice by genomic hypomethylation. Science 300:489-492, 2003
23. Jones PA: The DNA methylation paradox. Trends Genet 15:34-37, 1999
24. Singal R, Wang SZ, Sargent T, et al: Methylation of promoter proximal-transcribed sequences of an embryonic globin gene inhibits transcription in primary erythroid cells and promotes formation of a cell type-specific methyl cytosine binding complex. J Biol Chem 277: 1897-1905, 2002
25. Tate PH, Bird AP: Effects of DNA methylation on DNA-binding proteins and gene expression. Curr Opin Genet Dev 3:226-231, 1993
26. Prokhortchouk E, Hendrich B: Methyl-CpG binding proteins and cancer: Are MeCpGs more important than MBDs? Oncogene 21: 5394-5399, 2002
27. Singal R, Ferris R, Little JA, et al: Methylation of the minimal promoter of an embryonic globin gene silences transcription in primary erythroid cells. Proc Natl Acad Sci U S A 94:13724-13729, 1997
28. Singal R, van Wert J, Bashambu M: Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells. Cancer Res 61:4820-4826, 2001
29. Prokhortchouk A, Hendrich B, Jorgensen H, et al: The p120 catenin partner Kaiso is a DNA methylation-dependent transcriptional repressor. Genes Dev 15:1613-1618, 2001
30. Bender CM, Zingg JM, Jones PA: DNA methylation as a target for drug design. Pharm Res 15:175-187, 1998
31. Tamaru H, Selker EU: A histone H3 methyltransferase controls DNA methylation in Neurospora crassa. Nature 414:277-283, 2001
32. Fahrner JA, Eguchi S, Herman JG, et al: Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 62:7213-7218, 2002
33. Baylin SB, Herman JG: DNA hypermethylation in tumorigenesis: Epigenetics joins genetics. Trends Genet 16:168-174, 2000
34. Ehrlich M: DNA methylation in cancer: Too much, but also too little. Oncogene 21:5400-5413, 2002
35. Clark SJ, Melki J: DNA methylation and gene silencing in cancer: Which is the guilty party? Oncogene 21:5380-5387, 2002
36. Virmani AK, Rathi A, Sathyanarayana UG, et al: Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin Cancer Res 7:1998-2004, 2001
37. Kawakami K, Brabender J, Lord RV, et al: Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 92:1805-1811, 2000
38. Dobrovic A, Simpfendorfer D: Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res 57:3347-3350, 1997
39. Chan KY, Ozcelik H, Cheung AN, et al: Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res 62:4151-4156, 2002
40. Herman JG, Merlo A, Mao L, et al: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525-4530, 1995
41. Sanchez-Cespedes M, Esteller M, Wu L, et al: Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 60:892-895, 2000
42. Villuendas R, Sanchez-Beato M, Martinez JC, et al: Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. Am J Pathol 153:887-997, 1998
43. Harden SV, Tokumaru Y, Westra WH, et al: Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res 9:1370-1375, 2003
44. Graft JR, Herman JG, Lapidus RG, et al: E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 55:5195-5199, 1995
45. Graff JR, Greenberg VE, Herman JG, et al: Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma. Cancer Res 58:2063-2066, 1998
46. Waki T, Tamura G, Tsuchiya T, et al: Promoter methylation status of E-cadherin, hMLH1, and p16 genes in nonneoplastic gastric epithelia. Am J Pathol 161:399-403, 2002
47. Yang X, Yan L, Davidson NE: DNA methylation in breast cancer. Endocr Relat Cancer 8:115-127, 2001
48. Li LC, Chui R, Nakajima K, et al: Frequent methylation of estrogen receptor in prostate cancer: Correlation with tumor progression. Cancer Res 60:702-706, 2000
49. Lee WH, Morton RA, Epstein JI, et al: Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A 91:11733-11737, 1994
50. Esteller M, Corn PG, Urena JM, et al: Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 58:4515-1518, 1998
51. Veigl ML, Kasturi L, Olechnowicz J, et al: Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A 95:8698-8702, 1998
52. Kondo E, Furukawa T, Yoshinaga K, et al: Not hMSH2 but hMLH1 is frequently silenced by hypermethylation in endometrial cancer but rarely silenced in pancreatic cancer with microsatellite instability. Int J Oncol 17:535-541, 2000
53. Strathdee G, MacKean MJ, Illand M, et al: A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18:2335-2341, 1999
54. Esteller M, Garcia-Foncillas J, Andion E, et al: Inactivation of the DMA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354, 2000
55. Melki JR, Vincent PC, Clark SJ: Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 59:3730-3740, 1999
56. Garcia MJ, Martinez-Delgado B, Cebrian A, et al: Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin's and CD30-Positive non-Hodgkin's lymphomas. Am J Pathol 161:1007-1013, 2002
57. Herman JG, Jen J, Merlo A, et al: Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 56:722-727, 1996
58. Agathanggelou A, Honorio S, Macartney DP, et al: Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 20:1509-1518, 2001
59. Morrissey C, Martinez A, Zatyka M, et al: Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res 61: 7277-7281, 2001
60. Kwong J, Lo KW, To KF, et al: Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res 8:131-137, 2002
61. Stirzaker C, Millar DS, Paul CL, et al: Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors. Cancer Res 57:2229-2237, 1997
62. Gonzalez-Gomez P, Bello MJ, Alonso ME, et al: CpG island methylation status and mutation analysis of the RB1 gene essential promoter region and protein-binding pocket domain in nervous system tumours. Br J Cancer 88:109-114, 2003
63. Di Croce L, Raker VA, Corsaro M, et al: Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295:1079-1082, 2002
64. Tsou JA, Hagen JA, Carpenter CL, et al: DNA methylation analysis: A powerful new tool for lung cancer diagnosis. Oncogene 21:5450-5461, 2002
65. Catteau A, Morris JR: BRCA1 methylation: A significant role in tumour development? Semin Cancer Biol 12:359-371, 2002
66. Leone G, Teofili L, Voso MT, et al: DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 87:1324-1341, 2002
67. Uchida T, Kinoshita T, Nagai H, et al: Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 90:1403-1409, 1997
68. Toyota M, Kopecky KJ, Toyota MO, et al: Methylation profiling in acute myeloid leukemia. Blood 97:2823-2829, 2001
69. Feinberg AP, Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301:89-92, 1983
70. Kim YI, Giuliano A, Hatch KD, et al: Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma. Cancer 74:893-899, 1994
71. Lin CH, Hsieh SY, Sheen IS, et al: Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res 61:4238-4243, 2001
72. Bedford MT, van Helden PD: Hypomethylation of DNA in pathological conditions of the human prostate. Cancer Res 47:5274-5276, 1987
73. Okano M, Bell DW, Haber DA, et al: DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99:247-257, 1999
74. Hansen RS, Wijmenga C, Luo P, et al: The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. Proc Natl Acad Sci U S A 96:14412-14417, 1999
75. Feinberg AP, Vogelstein B: Hypomethylation of ras oncogenes in primary human cancers. Biochem Biophys Res Commun 111:47-54, 1983
76. Alves G, Tatro A, Fanning T: Differential methylation of human LINE-1 retrotransposons in malignant cells. Gene 176:39-44, 1996
77. Singer MF, Krek V, McMillan JP, et al: LINE-1: A human transposable element. Gene 135:183-188, 1993
78. Tuck-Muller CM, Narayan A, Tsien F, et al: DNA hypomethylation and unusual chromosome instability in cell lines from ICF syndrome patients. Cytogenet Cell Genet 89:121-128, 2000
79. Jurgens B, Schmitz-Drager BJ, Schulz WA: Hypomethylation of L1 LINE sequences prevailing in human urothelial carcinoma. Cancer Res 56:5698-5703, 1996
80. Sibani S, Christensen B, O'Ferrall E, et al: Characterization of six novel mutations in the methylenetetrahydrofolate reductase (MTHFR) gene in patients with homocystinuria. Hum Mutat 15:280-287, 2000
81. Bailey LB, Gregory JF III: Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: Metabolic significance, risks and impact on folate requirement. J Nutr 129:919-922, 1999
82. Gershoni-Baruch R, Dagan E, Israeli D, et al: Association of the C677T polymorphism in the MTHFR gene with breast and/or ovarian cancer risk in Jewish women. Eur J Cancer 36:2313-2316, 2000
83. Song C, Xing D, Tan W, et al: Methylenetetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population. Cancer Res 61: 3272-3275, 2001
84. Miao X, Xing D, Tan W, et al: Susceptibility to gastric cardia adenocarcinoma and genetic polymorphisms in methylenetetrahydrofolate reductase in an at-risk Chinese population. Cancer Epidemiol Biomarkers Prev 11:1454-1458, 2002
85. Wiemels JL, Smith RN, Taylor GM, et al: Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia. Proc Natl Acad Sci U S A 98:4004-4009, 2001
86. Chen J, Giovannucci E, Kelsey K, et al: A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 56:4862-4864, 1996
87. Kim YI, Pogribny IP, Salomon RN, et al: Exon-specific DNA hypomethylation of the p53 gene of rat colon induced by dimethylhydrazine: Modulation by dietary folate. Am J Pathol 149: 1129-1137, 1996
88. Christman JK, Sheikhnejad G, Dizik M, et al: Reversibility of changes in nucleic acid methylation and gene expression induced in rat liver by severe dietary methyl deficiency. Carcinogenesis 14:551-557, 1993
89. Pogribny IP, Miller BJ, James SJ: Alterations in hepatic p53 gene methylation patterns during tumor progression with folate/methyl deficiency in the rat. Cancer Lett 115:31-38, 1997
90. Friso S, Choi SW, Girelli D, et al: A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci U S A 99:5606-5611, 2002
91. Marugame T, Tsuji E, Kiyohara C, et al: Relation of plasma folate and methylenetetrahydrofolate reductase C677T polymorphism to colorectal adenomas. Int J Epidemiol 32:64-66, 2003
92. Fraga MF, Esteller M: DNA methylation: A profile of methods and applications. Biotechniques 33:632, 634, 636-649, 2002
93. Singal R, Grimes SR: Microsoft Word macro for analysis of cytosine methylation by the bisulfite deamination reaction. Biotechniques 30: 116-120, 2001
94. Goessl C, Krause H, Muller M, et al: Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 60:5941-5945, 2000
95. Usadel H, Brabender J, Danenberg KD, et al: Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 62:371-375, 2002
96. Kersting M, Friedl C, Kraus A, et al: Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol 18:3221-3229, 2000
97. Esteller M, Sanchez-Cespedes M, Rosell R, et al: Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59:67-70, 1999
98. Silva JM, Dominguez G, Garcia JM, et al: Presence of tumor DNA in plasma of breast cancer patients: Clinicopathological correlations. Cancer Res 59:3251-3256, 1999
99. Evron E, Dooley WC, Umbricht CB, et al: Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 357: 1335-1336, 2001
100. Dominguez G, Carballido J, Silva J, et al: P14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin Cancer Res 8:980-985, 2002
101. Zou HZ, Yu BM, Wang ZW, et al: Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin Cancer Res 8:188-191, 2002
102. OZ Wong IH, Lo YM, Yeo W, et al: Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin Cancer Res 6:3516-3521, 2000
103. Maeda K, Kawakami K, Ishida Y, et al: Hypermethylation of the CDKN2A gene in colorectal cancer is associated with shorter survival. Oncol Rep 10:935-938, 2003
104. Yi J, Wang ZW, Gang H, et al: P16 gene methylation in colorectal cancers associated with Duke's staging. World J Gastroenterol 7:722-725, 2001
105. Tomizawa Y, Kohno T, Kondo H, et al: Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin Cancer Res 8:2362-2368, 2002
106. Ng CS, Zhang J, Wan S, et al: Tumor p16M is a possible marker of advanced stage in non-small cell lung cancer. J Surg Oncol 79:101-106, 2002
107. Hayashi M, Tokuchi Y, Hashimoto T, et al: Reduced HIC-1 gene expression in non-small cell lung cancer and its clinical significance. Anticancer Res 21:535-540, 2001
108. Maruyama R, Toyooka S, Toyooka KO, et al: Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 8:514-519, 2002
109. Arnold CN, Goel A, Boland CR: Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 106:66-73, 2003
110. Plumb JA, Strathdee G, Sludden J, et al: Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 60:6039-6044, 2000
111. Lubbert M: DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: Clinical results and possible mechanisms of action. Curr Top Microbiol Immunol 249:135-164, 2000
112. Strathdee G, Brown R: Epigenetic cancer therapies: DNA methyltransferase inhibitors. Expert Opin Investig Drugs 11:747-754, 2002
113. Coffin J, Eisenhauer E: DNA methyltransferase inhibitors-state of the art. Ann Oncol 13:1699-1716, 2002
114. Cheng JC, Matsen CB, Gonzales FA, et al: Inhibition of DMA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 95:399-409, 2003
115. Thiagalingam S, Cheng KH, Lee HJ, et al: Histone deacetylases: Unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 983:84-100, 2003
116. Santini V, Kantarjian HM, Issa JP: Changes in DNA methylation in neoplasia: Pathophysiology and therapeutic implications. Ann Intern Med 134: 573-586, 2001
117. Juttermann R, Li E, Jaenisch R: Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci U S A 91:11797-11801, 1994
118. D'Incalci M, Covey JM, Zaharko DS, et al: DNA alkali-labile sites induced by incorporation of 5-aza-2′-deoxycytidine into DNA of mouse leukemia L1210 cells. Cancer Res 45:3197-3202, 1985
119. Momparler RL, Bouchard J, Onetto N, et al: 5-aza-2′-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation. Leuk Res 8:181-185, 1984
120. Wilson VL, Jones PA, Momparler RL: Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2′-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res 43:3493-3496, 1983
121. Steuber CP, Krischer J, Holbrook T, et al: Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: A Pediatric Oncology Group randomized phase II study. J Clin Oncol 14:1521-1525, 1996
122. Kantarjian HM, O'Brien S, Cortes J, et al: Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98:522-528, 2003
123. Daskalakis M, Nguyen TT, Nguyen C, et al: Demethylation of a hypermethylated P15/ INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 100:2957-2964, 2002
124. Robert MF, Morin S, Beaulieu N, et al: DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 33:61-65, 2003
125. Cameron EE, Bachman KE, Myohanen S, et al: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103-107, 1999
126. Piekarz RL, Robey R, Sandor V, et al: Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report. Blood 98:2865-2868, 2001
127. He LZ, Tolentino T, Grayson P, et al: Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 108:1321-1330, 2001
128. Manev H, Uz T: DNA hypomethylating agents 5-aza-2′-deoxycytidine and valproate increase neuronal 5-lipoxygenase mRNA. Eur J Pharmacol 445:149-150, 2002
129. Segura-Pacheco B, Trejo-Becerril C, Perez-Cardenas E, et al: Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res 9:1596-1603, 2003
130. Phiel CJ, Zhang F, Huang EY, et al: Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276:36734-36741, 2001
131. Sato N, Maehara N, Su GH, et al: Effects of 5-aza-2′-deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness. J Natl Cancer Inst 95:327-330, 2003